[Polychemotherapy of advanced soft tissue sarcomas with 4'-epi-doxorubicin (4'-Epi-DX) and cisplatin (DDP)]. 1986

H Sauer, and W Mair, and U Fink, and H Rückle, and I Mjaaland, and W Wilmanns

34 patients with locally advanced or metastatic soft tissue sarcoma were treated with 4'-epi-adriamycin (4'-Epi-DX: 45 mg/m2 day 1 + 2) and cisplatinum (DDP: 90 mg/m2 day 2). If leukocyte- or plateletnadirs during the previous interval were above 2,000/mm3 or 70,000/mm3 the dose of 4'-Epi-DX was escalated for 5 mg/m2 per treatment day. One patient died tumor-related soon after the first treatment cycle. In 33 evaluable patients 4 (12%) complete remissions, 10 (30%) partial remissions and 15 (46%) no changes were observed. 4 patients (12%) had primary progressive disease under treatment. In 6 patients treatment was stopped because of side effects: 4 intractable nausea and vomiting, 1 ototoxicity, 1 supposed cardiomyopathy. Hematotoxicity was not a limiting factor in this treatment regimen.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H Sauer, and W Mair, and U Fink, and H Rückle, and I Mjaaland, and W Wilmanns
July 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H Sauer, and W Mair, and U Fink, and H Rückle, and I Mjaaland, and W Wilmanns
November 1984, Cancer treatment reports,
H Sauer, and W Mair, and U Fink, and H Rückle, and I Mjaaland, and W Wilmanns
January 2000, Journal of surgical oncology,
H Sauer, and W Mair, and U Fink, and H Rückle, and I Mjaaland, and W Wilmanns
June 2020, American journal of clinical oncology,
H Sauer, and W Mair, and U Fink, and H Rückle, and I Mjaaland, and W Wilmanns
August 2000, Investigational new drugs,
H Sauer, and W Mair, and U Fink, and H Rückle, and I Mjaaland, and W Wilmanns
January 2010, Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association,
H Sauer, and W Mair, and U Fink, and H Rückle, and I Mjaaland, and W Wilmanns
April 1992, Annals of oncology : official journal of the European Society for Medical Oncology,
H Sauer, and W Mair, and U Fink, and H Rückle, and I Mjaaland, and W Wilmanns
January 1988, Seminars in surgical oncology,
H Sauer, and W Mair, and U Fink, and H Rückle, and I Mjaaland, and W Wilmanns
January 1985, Voprosy onkologii,
H Sauer, and W Mair, and U Fink, and H Rückle, and I Mjaaland, and W Wilmanns
January 1989, Cancer treatment and research,
Copied contents to your clipboard!